BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 25432738)

  • 1. Expression profiling of circulating tumor cells in metastatic breast cancer.
    Lang JE; Scott JH; Wolf DM; Novak P; Punj V; Magbanua MJ; Zhu W; Mineyev N; Haqq CM; Crothers JR; Esserman LJ; Tripathy D; van 't Veer L; Park JW
    Breast Cancer Res Treat; 2015 Jan; 149(1):121-31. PubMed ID: 25432738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
    Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
    Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
    Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
    Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
    [No Abstract]   [Full Text] [Related]  

  • 4. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients.
    Magbanua MJ; Sosa EV; Roy R; Eisenbud LE; Scott JH; Olshen A; Pinkel D; Rugo HS; Park JW
    Cancer Res; 2013 Jan; 73(1):30-40. PubMed ID: 23135909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling.
    Magbanua MJ; Park JW
    Methods; 2013 Dec; 64(2):114-8. PubMed ID: 23896286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.
    Lang JE; Ring A; Porras T; Kaur P; Forte VA; Mineyev N; Tripathy D; Press MF; Campo D
    Ann Surg Oncol; 2018 Aug; 25(8):2261-2270. PubMed ID: 29868978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.
    Sieuwerts AM; Mostert B; Bolt-de Vries J; Peeters D; de Jongh FE; Stouthard JM; Dirix LY; van Dam PA; Van Galen A; de Weerd V; Kraan J; van der Spoel P; Ramírez-Moreno R; van Deurzen CH; Smid M; Yu JX; Jiang J; Wang Y; Gratama JW; Sleijfer S; Foekens JA; Martens JW
    Clin Cancer Res; 2011 Jun; 17(11):3600-18. PubMed ID: 21505063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer.
    Ueo H; Sugimachi K; Gorges TM; Bartkowiak K; Yokobori T; Müller V; Shinden Y; Ueda M; Ueo H; Mori M; Kuwano H; Maehara Y; Ohno S; Pantel K; Mimori K
    Br J Cancer; 2015 Apr; 112(9):1519-26. PubMed ID: 25880010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM
    Lampignano R; Yang L; Neumann MHD; Franken A; Fehm T; Niederacher D; Neubauer H
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-stage microfluidic chip for selective isolation of circulating tumor cells (CTCs).
    Hyun KA; Lee TY; Lee SH; Jung HI
    Biosens Bioelectron; 2015 May; 67():86-92. PubMed ID: 25060749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells.
    Ge F; Zhang H; Wang DD; Li L; Lin PP
    Oncotarget; 2015 Sep; 6(29):27049-64. PubMed ID: 26267323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
    Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.